

**Supplementary Table S1.** The annual positivity of autoantibodies.

Autoantibody	Baseline	1 <sup>st</sup> year	2 <sup>nd</sup> year	3 <sup>rd</sup> year
Ro/SSA	217/252 (86%)	195/230 (85%)	195/226 (86%)	168/192 (88%)
La/SSB	123/251 (49%)	120/227 (53%)	118/221 (53%)	89/189 (47%)
Centromere	23/234 (10%)	23/223 (10%)	22/222 (10%)	15/192 (8%)
RNP	5/142 (4%)	11/188 (6%)	14/216 (6%)	13/189 (7%)
dsDNA	7/234 (3%)	19/223 (9%)	21/223 (9%)	18/192 (9%)
RF	160/245 (65%)	147/232 (63%)	152/238 (64%)	118/203 (58%)
IU/mL (IQR)	44 (11–101)	40 (10–94)	38 (8–88)	34 (5–86)

dsDNA: double stranded DNA; RF: rheumatoid factor; RNP: ribonucleoprotein; SSA: Sjögren's syndrome A; SSB: Sjögren's syndrome B.

**Supplementary Table S2.** Changes in autoantibody profile according to the medication use.

		Baseline	2 <sup>nd</sup> -year follow-up	<i>p</i> -value*
<b>Hydroxychloroquine</b>				
Ro/SSA	HCQ	160/182 (88)	140/157 (89)	>0.999
	Non-HCQ	57/70 (81)	55/69 (80)	>0.999
La/SSB	HCQ	99/181 (55)	88/155 (57)	0.648
	Non-HCQ	24/70 (34)	30/66 (45)	<b>0.035</b>
Centromere	HCQ	14/164 (9)	14/155 (9)	>0.999
	Non-HCQ	9/70 (13)	8/67 (12)	>0.999
RNP	HCQ	2/97 (2)	7/64 (11)	0.625
	Non-HCQ	3/45 (7)	7/152 (5)	>0.999
dsDNA	HCQ	5/165 (3)	12/156 (8)	<b>0.039</b>
	Non-HCQ	2/69 (3)	9/67 (13)	<b>0.016</b>
<b>Oral glucocorticoids</b>				
Ro/SSA	GC	101/115 (88)	71/82 (87)	>0.999
	Non-GC	116/137 (85)	133/154 (86)	>0.999
La/SSB	GC	62/115 (54)	41/80 (51)	>0.999
	Non-GC	61/136 (45)	83/150 (55)	<b>0.012</b>
Centromere	GC	12/109 (11)	6/79 (8)	0.625
	Non-GC	11/125 (9)	16/145 (11)	>0.999
RNP	GC	3/70 (4)	5/51 (10)	0.375
	Non-GC	2/72 (3)	2/78 (3)	>0.999
dsDNA	GC	3/111 (3)	5/80 (6)	0.625
	Non-GC	4/123 (3)	17/146 (12)	<b>0.008</b>

\**p*-values were calculated by exact McNemar test.

dsDNA: double stranded DNA; RNP: ribonucleoprotein; SSA: Sjögren's syndrome A; SSB: Sjögren's syndrome B.

**Supplementary Table S3.** Binary logistic analysis of autoantibodies prognostic for glandular and extra-glandular damage at the third-year follow-up.

Dependent variable (Positive vs. negative)	Univariate model Odds Ratio (95% CI)	Multivariate model* Odds Ratio (95% CI)
<b>Extra-glandular manifestations</b>		
Ro/SSA	1.456 (0.533–3.982)	1.184 (0.463–3.028)
La/SSB	1.042 (0.569–1.907)	1.432 (0.768–2.671)
Centromere	0.745 (0.243–2.281)	0.885 (0.324–2.419)
dsDNA	0.531 (0.064–4.420)	0.461 (0.085–2.488)
<b>Solid organ damage</b>		
Ro/SSA	1.397 (0.310–6.303)	0.755 (0.134–4.269)
La/SSB	1.849 (0.739–4.627)	<b>3.200 (1.006–10.177)</b>
Centromere	0.892 (0.195–4.079)	0.815 (0.159–4.166)
<b>Salivary flow impairment</b>		
Ro/SSA	1.722 (0.811–3.658)	2.436 (0.899–6.596)
La/SSB	1.869 (1.097–3.183)	<b>2.700 (1.331–5.476)</b>
Centromere	3.849 (1.115–13.282)	<b>7.720 (1.513–39.396)</b>
<b>Ocular structural abnormalities</b>		
Ro/SSA	2.139 (1.002–4.566)	<b>4.902 (1.646–14.598)</b>
La/SSB	0.988 (0.576–1.697)	0.826 (0.366–1.863)
Centromere	1.849 (0.608–5.621)	8.397 (0.916–76.957)
dsDNA	1.075 (0.211–5.468)	

\*Age, hydroxychloroquine, methotrexate and oral glucocorticoids use were adjusted.

dsDNA: double stranded DNA; RNP: ribonucleoprotein; SSA: Sjögren's syndrome A; SSB: Sjögren's syndrome B.